Sovargen

News

Angelini Pharma has licensed a preclinical-stage mTOR inhibitor from South Korean biotech Sovargen with potential for genetic forms of epilepsy.

Oncology

At ASCO 26, Daiichi Sankyo leaders Ken Keller and John Tsai chatted with pharmaphorum about their big year of oncology launches, halfway in.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.